860
Views
6
CrossRef citations to date
0
Altmetric
Review

Evaluating topical JAK inhibitors as a treatment option for atopic dermatitis

, ORCID Icon, ORCID Icon, &
Pages 221-231 | Received 31 Aug 2021, Accepted 11 Oct 2021, Published online: 22 Oct 2021

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Mitsumasa Kishimoto, Gautam A. Deshpande, Sho Fukui, Yoshinori Komagata, Manabu Ohyama & Shinya Kaname. (2023) Upadacitinib for moderate-to-severe atopic dermatitis, in adults and adolescents 12 years and older: review of international and Japanese populations. Expert Review of Clinical Immunology 19:1, pages 19-35.
Read now

Articles from other publishers (5)

Mircea Tampa, Cristina Iulia Mitran, Madalina Irina Mitran & Simona Roxana Georgescu. (2023) A New Horizon for Atopic Dermatitis Treatments: JAK Inhibitors. Journal of Personalized Medicine 13:3, pages 384.
Crossref
Karolina Makowska, Joanna Nowaczyk, Leszek Blicharz, Anna Waśkiel-Burnat, Joanna Czuwara, Małgorzata Olszewska & Lidia Rudnicka. (2023) Immunopathogenesis of Atopic Dermatitis: Focus on Interleukins as Disease Drivers and Therapeutic Targets for Novel Treatments. International Journal of Molecular Sciences 24:1, pages 781.
Crossref
Elisha M. Myers, Patrick O. Perche, Joseph L. Jorizzo & Steven R. Feldman. (2022) Reducing costs in atopic dermatitis. Dermatologic Therapy 35:11.
Crossref
Cem Akin, Michel Arock & Peter Valent. (2022) Tyrosine kinase inhibitors for the treatment of indolent systemic mastocytosis: Are we there yet?. Journal of Allergy and Clinical Immunology 149:6, pages 1912-1918.
Crossref
Rohan Singh, Sindhuja Koppu, Patrick O. Perche & Steven R. Feldman. (2021) The Cytokine Mediated Molecular Pathophysiology of Psoriasis and Its Clinical Implications. International Journal of Molecular Sciences 22:23, pages 12793.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.